Release primary care capacity with home ACR testing
Fully funded programmes are already being deployed in GP practices across the UK. Find out if home urinary ACR screening is available in your area.
Funded programmes to shift testing from the practice to the home
Healthy.io in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, are offering substantial funding opportunities to release primary care capacity by allowing people at increased risk of chronic kidney disease (CKD) to complete their annual urine test at home.
This nationally significant programme, announced by the Department of Health and Social Care , uses tried and tested technology to improve outcomes in essential annual kidney health testing for people with diabetes and hypertension, closing gaps around poor compliance with national recommendations on testing which is known to be beneficial in the early detection and prevention of CKD.
Funded programmes have been adopted in 40% of integrated care systems and are currently being deployed in a number of GP practices across the UK. Find out if the service is available in your area.
Key benefits
- Improve uptake of annual urinary ACR care process to ensure early identification of patients with CKD
- Quick and easy implementation - set up the service in your practice in under 1 hour
- Minimise workload of chasing up missed ACR tests and reduce backlogs in chronic disease management
- Engage previously hard-to-reach patients; no appointment needed so vulnerable patients can stay at home
- Abnormal results flagged for quick follow-up and integrated into SystmOne / EMIS
- All stages of the service will be fulfilled by Healthy.io once your practice is set up
Send
We send ACR test kits directly to eligible patients' homes with their prior consent
Test
Patients self-test using our test kit and smartphone app, which guides them easily
Review
Results are analysed and uploaded to SystmOne or EMIS workflows in real time
Clinical-grade testing from home
The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.
The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).
Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).
The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.
found the test 'easy' or 'very
easy' to use
preferred testing at home
vs. testing at the clinic
would recommend this service
to a friend
Find out if your practice is fully funded
Please complete the form to find out if a fully funded scheme is already running in your area. Our team will check your practice’s eligibility and provide next steps.
By providing this information, you consent to receive relevant content from Healthy.io. (You may opt out at any point.) For more information, visit our Privacy Policy.
- Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024
